Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer

Maj K. Kjeldsen, Morten Jørgensen, Dina Sofie B. Grønseth, Martin Schønemann-Lund, Gitte Bettina Nyvang, Charlotte Aaquist Haslund, Anja Oer Knudsen, Anne Krejbjerg Motavaf, Susanne Malander, Maarit Anttila, Gabriel Lindahl, Johanna Mäenpää, Maria Dimoula, Theresa L. Werner, Trine Zeeberg Iversen, Sakari Hietanen, Lars Fokdal, Hanna Dahlstrand, Line Bjørge, Michael J. BirrerMansoor R. Mirza, Maria Rossing

Research output: Contribution to journalArticleScientificpeer-review

2 Downloads (Pure)

Abstract

SIGNIFICANCE: The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing precision oncology in future clinical practice.

Original languageEnglish
Pages (from-to)3190-3200
Number of pages11
JournalCancer research communications
Volume4
Issue number12
DOIs
Publication statusPublished - Dec 2024
Publication typeA1 Journal article-refereed

Publication forum classification

  • Publication forum level 1

ASJC Scopus subject areas

  • General Medicine
  • Obstetrics and Gynaecology
  • Oncology

Fingerprint

Dive into the research topics of 'Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer'. Together they form a unique fingerprint.

Cite this